PURPOSE: Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT. PATIENTS AND METHODS: A cohort of 529 men with advanced prostate cancer treated with ADT was genotyped for 129 DNA polymorphisms distributed across 20 genes involved in androgen metabolism. RESULTS: Three polymorphisms in separate genes (CYP19A1, HSD3B1, and HSD17B4) were significantly (P < .01) associated with time to progression (TTP) during ADT, remaining so in multivariate analyses and after correcting for the number of hypotheses tested. Individuals carrying more than one of the polymorphisms associated with improved TTP demonstrated a better response to therapy than individuals carrying zero or one (P < .0001). CONCLUSION: This report is the first to examine the influence of inherited variation in the androgen metabolic pathway on the efficacy of ADT, establishing the importance of pharmacogenomics on individual's response to this therapy. At least two potential clinical benefits may be realized from this study. The first is prognostic -genotyping patients at these loci may yield important information that could improve efficacy prediction. The second is therapeutic -these results shed light on the pathways that govern response to ADT. Drugs could be developed (or may already exist) to inhibit or augment these targets to improve ADT efficacy.
PURPOSE: Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT. PATIENTS AND METHODS: A cohort of 529 men with advanced prostate cancer treated with ADT was genotyped for 129 DNA polymorphisms distributed across 20 genes involved in androgen metabolism. RESULTS: Three polymorphisms in separate genes (CYP19A1, HSD3B1, and HSD17B4) were significantly (P < .01) associated with time to progression (TTP) during ADT, remaining so in multivariate analyses and after correcting for the number of hypotheses tested. Individuals carrying more than one of the polymorphisms associated with improved TTP demonstrated a better response to therapy than individuals carrying zero or one (P < .0001). CONCLUSION: This report is the first to examine the influence of inherited variation in the androgen metabolic pathway on the efficacy of ADT, establishing the importance of pharmacogenomics on individual's response to this therapy. At least two potential clinical benefits may be realized from this study. The first is prognostic -genotyping patients at these loci may yield important information that could improve efficacy prediction. The second is therapeutic -these results shed light on the pathways that govern response to ADT. Drugs could be developed (or may already exist) to inhibit or augment these targets to improve ADT efficacy.
Authors: Kathryn L Penney; Saumyadipta Pyne; Fredrick R Schumacher; Jennifer A Sinnott; Lorelei A Mucci; Peter L Kraft; Jing Ma; William K Oh; Tobias Kurth; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; David J Hunter; Matthew L Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-26 Impact factor: 4.254
Authors: Manish Kohli; Shaun M Riska; Douglas W Mahoney; High S Chai; David W Hillman; David N Rider; Brian A Costello; Rui Qin; Jatinder Lamba; Deepak M Sahasrabudhe; James R Cerhan Journal: Mayo Clin Proc Date: 2012-03 Impact factor: 7.616
Authors: Jason W D Hearn; Ghada AbuAli; Chad A Reichard; Chandana A Reddy; Cristina Magi-Galluzzi; Kai-Hsiung Chang; Rachel Carlson; Laureano Rangel; Kevin Reagan; Brian J Davis; R Jeffrey Karnes; Manish Kohli; Donald Tindall; Eric A Klein; Nima Sharifi Journal: Lancet Oncol Date: 2016-08-27 Impact factor: 41.316
Authors: Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544